铜绿假单胞菌注射液联合多西他赛和顺铂治疗肺癌所致恶性胸腔积液疗效观察

目的观察铜绿假单胞菌注射液联合DP方案（多西他赛＋顺铂）化疗治疗非小细胞肺癌所致恶性胸腔积液的效果及安全性。方法非小细胞肺癌并恶性胸腔积液患者66例，随机分为观察组37例和对照组29例，2组均应用DP方案化疗2个周期。注射化疗药物7d后经B超证实胸腔积液排净或胸腔积液引流量〈50mL／d时，观察组经胸腔灌注铜绿假单胞菌注射液，对照组经胸腔灌注白细胞介素-2。胸腔灌注治疗结束后6周评价2组疗效并观察不良反应发生情况。结果观察组有效率（89．2％）高于对照组（69．0％）（P〈0．05）；观察组发热及胸痛发生率分别为43．2％和48．6％，对照组分别为为24．1％和27．6％，2组比较差异无统计学意义（P〉0．05）。结论铜绿假单胞菌注射液胸腔灌注联合DP方案治疗非小细胞肺癌恶性胸腔积液疗效满意，不良反应轻。

Therapeutic effect of PA-MSHA injection plus docetaxel and cisplatincil on lung cancer induced malignant pleural effusion

Objective To observe the efficacy and safety of PA-MSHA injection plus docetaxel and cisplatincil （DP scheme） in the treatment of malignant pleural effusion in patients with non-small cell lung cancer （NSCLC）. Methods Sixty-six NSCLC patients complicated with malignant pleural effusion were randomly divided into observation group （n= 37） and control group （n=29）. Both groups received 2 cycles of DP scheme. When ultrasonography showed no pleural effusion or the pleural effusion volume was less than 50 mL/d after chemotherapy for 7 days, observation group was given intrapleural injection of PA-MSHA, and control group was given intrapleural injection of interleukin-2. The remission rate and toxicities were observed 6 weeks after therapy. Results The effective rate was 89.2% in observation group, higher than that in control group （69.0%） （P〈0.05）. The incidence rates of fever and chest pain were 43.2% and 48.6% in observation group, showing no significant differences in comparison with control group （24.1%, 27.6%） （P〉0.05）. Conclusions Intrapleural injection of PA-MSHA combined with DP scheme is effective for malignant pleural effusion in NSCLC patients, and the toxicity is mild.